Nystatin Oral Suspension, USP 100,000 units per mL, Cherry/Peppermint Flavor, Rx ONLY, packaged in a) 16 fl oz (473 mL) NDC 0121-0868-16; b) 2 fl oz (60 mL) NDC 0121-0868-02; Manufactured by: Pharmaceutical Associates, Inc. Greenville, SC 29605
Published August 18, 2021 · Recall initiated: July 29, 2021
Summary
FDA records drug Class II recall D-0721-2021, published August 18, 2021 and initiated July 29, 2021. Recalling firm: PAI Holdings, LLC. dba Pharmaceutical Associates Inc; Status: Terminated; Reported quantity: a) 1002 cases (12 bottles/case); b) 458 cases (24 bottles/case); Lot: Lots: a) C98F, C990 Exp. 30SEP2022, C9C2 Exp. 31OCT2022; b) C9E1 Exp. 31OCT2022. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Lack of CGMP: This recall is being carried out due to potential for carry over of Senna Syrup.
What to do
Voluntary: Firm initiated · Letter
Get an email if NYSTATIN has another recall
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Brand
- NYSTATIN
- Manufacturer
- PAI Holdings, LLC. dba Pharmaceutical Associates Inc
- Distributor
- Distributed Nationwide in the USA
- UPC
- 0301210868160
- Lot
- Lots: a) C98F, C990 Exp. 30SEP2022, C9C2 Exp. 31OCT2022; b) C9E1 Exp. 31OCT2022
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDANystatin Cream USP, (100,000 USP Nystatin Units), NET WT 15 g, Rx only, 15 g tube, Manufactured by Padagis,July 22, 2026
- FDAZyprexa Intramuscular, Olanzapine for Injection, 10 MG per Single Use Vial, Rx only, Marketed by: Lilly USA,August 18, 2021
- FDAEthosuximide Oral Solution USP 250 mg/5 mL, 16 fl oz (473 mL), Rx ONLY, Pharmaceutical Associates, Inc.August 18, 2021
- FDANystatin Oral Suspension, USP 100,000 units per mL, Cherry/Peppermint Flavor, 16 fl. oz. (473 mL), Rx only,August 19, 2020
- FDANystatin Oral Suspension, USP, 100,000 units per mL, Cherry/Peppermint Flavor, 16 fl oz (473 mL) bottle, RxApril 1, 2020
- FDANystatin Oral Suspension, USP 100,000 units per mL Cherry/Peppermint Flavor, 16 fl oz (473 mL) Rx Only, pai,February 5, 2020
Questions about this recall
Was Nystatin Oral Suspension, USP 100,000 units per mL, Cherry/Peppermint Flavor, Rx ONLY, packaged in a) 16 fl oz (473 mL) NDC 0121-0868-16; b) 2 fl oz (60 mL) NDC 0121-0868-02; Manufactured by: Pharmaceutical Associates, Inc. Greenville, SC 29605 recalled?
Yes. FDA published recall D-0721-2021 on August 18, 2021. Reported hazard: Lack of CGMP: This recall is being carried out due to potential for carry over of Senna Syrup.
What should I do if I have this product?
Voluntary: Firm initiated · Letter
How do I know if my unit is part of the recall?
Compare your product details with the notice. Brand: NYSTATIN. UPC: 0301210868160.